Vial and dose math, with the evidence and limits plainly stated.
Explore by goal. Ordered by evidence type, not by expected benefit. A study is not a recommendation; check the population, route and limitations.
17 entries in this selection
FDA label for a specific indication
FDA-approved drug — specific formulations and indications
Acquired, generalized hypoactive sexual desire disorder in premenopausal women under the labeled criteria. Study / source
Read evidence and cautions →FDA label for a specific indication
FDA-approved drug — specific formulations and indications
Weight reduction in the labeled population, alongside diet and physical activity. Study / source
Read evidence and cautions →FDA label for a specific indication
FDA-approved drug — specific formulations and indications
Excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight loss. Study / source
Read evidence and cautions →FDA label for a specific indication
FDA-approved drug — specific formulations and indications
Weight reduction in the labeled population, alongside diet and physical activity. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
Obesity studies assessed by FDA did not establish effectiveness for weight reduction. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
Knee pain in a retrospective human report; this design cannot establish treatment benefit. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
Weight reduction in a randomized human trial; trial doses are not an approved regimen. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
Anxiety symptoms in a comparative clinical study; this does not establish cognitive enhancement or an injection regimen. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
Neurological recovery after ischemic stroke in a comparative study, not cognitive enhancement in healthy people. Study / source
Read evidence and cautions →Human research — investigational use
Prescription compounded — not FDA approved
Historical diagnostic testing of growth hormone release; this does not establish an adult longevity regimen. Study / source
Read evidence and cautions →Human research — investigational use
Research-only / investigational — not FDA approved
A randomized sepsis trial found no clear mortality benefit. This is not evidence for routine wellness use. Study / source
Read evidence and cautions →Preclinical — cells or animals
Research-only / investigational — not FDA approved
Telomere biology in cultured cells; this does not establish longer human lifespan. Study / source
Read evidence and cautions →Preclinical — cells or animals
Research-only / investigational — not FDA approved
Collagen synthesis in cultured fibroblasts; this is not evidence for an injectable skin regimen. Study / source
Read evidence and cautions →Preclinical — cells or animals
Research-only / investigational — not FDA approved
Intestinal inflammation in preclinical models. Study / source
Read evidence and cautions →Preclinical — cells or animals
Research-only / investigational — not FDA approved
Metabolism and insulin sensitivity in cell and animal experiments. Study / source
Read evidence and cautions →Insufficient evidence for this compound
Research-only / investigational — not FDA approved
CJC-1295 alone: growth hormone secretion in healthy men. Study / source
Read evidence and cautions →Insufficient evidence for this compound
Research-only / investigational — not FDA approved
FDA reports no identified human exposure data for this fragment; results for full-length thymosin beta-4 cannot be assumed to apply. Study / source
Read evidence and cautions →Educational reference. The first cards are Dr. Axe’s own doses; the peptides from his book Heal Your Cells show published practitioner or label doses, named on each card. These examples do not select a treatment or dose for you. Check the route, formulation and instructions with your prescriber or pharmacist.
Common dose: 250–1,000 mcg daily, 5 days a week.
Typical cycle: 6 weeks on / 6 weeks off.
Source: Dr. Axe’s September 24, 2026 review feedback.
Common dose: 2.5–5 mg weekly.
Typical cycle: 4 to 8 weeks.
Source: Dr. Axe’s September 24, 2026 review feedback.
Common dose: 2 mg daily.
Typical cycle: 4 to 6 weeks.
Source: Dr. Axe’s September 24, 2026 review feedback.
Common dose: 100 mcg of each, nightly.
Typical cycle: 5 days on / 2 days off.
Source: Dr. Axe’s September 24, 2026 review feedback.
Daily protein target: Not set. Cellular Bloodwork Analysis →
Protein & resistance training: Include regular resistance training suited to your ability, alongside adequate protein, to help protect muscle while weight comes off.
Starting-dose comparison: 0.025–0.05 mg — 10–20% of the 0.25 mg labeled starting dose.
Adult weight reduction · subcutaneous injection · once weekly. Labeled starting period: Weeks 1–4 · starting dose.
Typical cycle: No micro-dose on/off cycle is specified in Dr. Axe’s material.
Dr. Axe’s educational position is to explore 10–20% of the standard labeled dose. This is arithmetic, not an FDA-labeled regimen or a proven equivalent treatment. This tool does not tell you to cut or change your prescription.
Existing labeled-dose source · Dose comparison and cautions →
Daily protein target: Not set. Cellular Bloodwork Analysis →
Protein & resistance training: Include regular resistance training suited to your ability, alongside adequate protein, to help protect muscle while weight comes off.
Starting-dose comparison: 0.25–0.5 mg — 10–20% of the 2.5 mg labeled starting dose.
Adult weight reduction · subcutaneous injection · once weekly. Labeled starting period: First 4 weeks · starting dose, not maintenance.
Typical cycle: No micro-dose on/off cycle is specified in Dr. Axe’s material.
Dr. Axe’s educational position is to explore 10–20% of the standard labeled dose. This is arithmetic, not an FDA-labeled regimen or a proven equivalent treatment. This tool does not tell you to cut or change your prescription.
Existing labeled-dose source · Dose comparison and cautions →
Common dose: 1.6 mg under the skin, twice a week.
Typical cycle: 6 to 12 months.
Caution: Not for people who are deliberately immunosuppressed, such as organ transplant patients.
Source: Zadaxin prescribing information
Common dose: 5–20 mg daily by intramuscular injection (30–100 mg per course).
Typical cycle: 3 to 10 days; repeat after 1 to 6 months.
Source: Thymalin product label (Russia) · Khavinson & Morozov, 2003
Common dose: 5–10 mg daily by injection.
Typical cycle: 10 to 20 days, 1 to 3 cycles a year.
Source: Ubie Doctor’s Note, reviewed by Yoshinori Abe, MD · Alzheimer’s Drug Discovery Foundation report
Common dose: 5 mg under the skin, 2 to 3 times a week.
Typical cycle: 8 to 12 weeks on / 4 weeks off.
Source: Iman Bar, MD
Common dose: 2–5 mg daily by injection in functional-medicine protocols. The FDA-labeled dose for Barth syndrome is 40 mg daily.
Typical cycle: 8 to 12 weeks on / 4 weeks off.
Common dose: 0.1% nasal drops (50 mcg per drop): 2–3 drops in each nostril, 4 times a day.
Typical cycle: 10 to 14 days.
Source: Semax product label (Russia)
Common dose: 0.15% nasal drops: 2 drops in each nostril, 3 times a day.
Typical cycle: 14 days; can repeat after 1 to 3 weeks.
Caution: Not for children under 18 or during pregnancy or breastfeeding.
Source: Selank product label (Peptogen)
Common dose: 100 mcg under the skin daily.
Typical cycle: No fixed cycle given.
Common dose: 1 mg under the skin at bedtime, 5 days on / 2 days off, in functional-medicine protocols. The FDA-labeled dose is 1.28 mg daily (Egrifta WR).
Typical cycle: 3 months on / 2 months off.
Caution: Not for active cancer, pregnancy or hypothalamic-pituitary disorders. IGF-1 and blood sugar need monitoring.
Source: Perfect B clinic protocol · Egrifta WR prescribing information
Need help interpreting this information? Explore care at The Health Institute.
